Improving health security and pandemic preparedness
The innovative pharmaceutical industry is committed to sharing the benefits of diagnostics, therapeutics, and vaccines equitably worldwide.
IFPMA and our members campaign to remove the barriers to sharing pathogens that cause influenza and diseases such as COVID-19. We play a critical role in preparing for and responding to future pandemics or health threats like antimicrobial resistance. This requires investing in R&D and building a robust portfolio of countermeasures before a health emergency. The industry also works to combat the threat from falsified medicines.
When it comes to climate change, the industry is minimizing its impact while developing new health technologies to help manage and mitigate effects on health.
When the COVID-19 pandemic hit, the innovative pharmaceutical industry came together with the broader global health community and responded with unprecedented speed and scale, overcoming major hurdles along the way.
The innovative pharmaceutical industry has played and will continue to play a critical role in pandemic preparedness response. IFPMA has a strong track record as a partner contributing knowhow and exploring solutions.
Together with the global health community, the innovative pharmaceutical industry works to improve seasonal influenza vaccine coverage and wider flu pandemic preparedness for the future.
Access to pathogens
A pathogen is an organism that causes disease. IFPMA represents the innovative pharmaceutical industry in policy discussions to make sure pathogens and their information are shared more rapidly and widely to protect public health.
IFPMA and our members are playing our part in driving a long-term, sustainable, multi-pronged strategy to fight the extremely serious threat of falsified medicines to global public health.
Innovative pharmaceutical companies are researching and developing new health technologies that help manage and mitigate effects on health from climate change, while minimizing the impact of their operations and products on the planet.
IFPMA helps lead the innovative pharmaceutical industry’s work on antimicrobial resistance (AMR). We raise awareness of the unique challenges in combating AMR and of measures that could establish economic conditions favorable to long-term investment into antibiotic R&D.